porna

Market Research Reports and Industry Reports

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care. Therapy areas - Oncology, Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia, Alzheimers and Melanoma are few select areas where newer therapies that are safer and more efficacious will reach the market. Many of these innovations promise a paradigm shift in the standard of care. The year 2012 has marked the beginning of this trend as many new blockbuster drug were approved and we also witnessed promising proof of concept data on many of the potential path breaking innovation. There are also major outcome clinical trials that will deliver data over the next few years and if positive, we will see the change in fortunes of many existing drugs that are on the market.
In the near term as well the sector continues to remain attractive, as cost containment initiatives, restructuring/deconsolidation, share repurchase program, M&A, emerging market growth potential and dividend policy continue to be encouraging. Over the next few years, the growth of the industry would be shaped up by a battle between fundamental growth drivers (Value added innovation) versus regulatory pressures to contain costs.

Global Biopharmaceutical Outlook 2013-Large Cap Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.

Key Topics Covered
Value Based Pricing- Strength of Innovation Vs Fiscal Pressures
Major therapy areas to shape up pharma business going forward
Europe Regulatory Pressures and Increasing Pro Generic Stance
Will US fall to Pricing Pressures?
Emerging Markets and their importance in Growth of Large Cap Pharma
Global Pharma -Drugs Losing Patent Protection By 2017
Impact of patent expiry in w.r.t. 2012 total revenue thru 2017
Global Pharma Research Pipeline (PhII And PhIII)- 2013
Global Pharma Milestones in 2013
Roche: Breast Cancer Franchise And Actemra To Drive Near Term Growth, And Multiple Blockbusters In Pipeline To Take Care Of Long Term Growth
GlaxoSmithKline: Next Generation Bronchodilators, Melanoma, Hiv And Emerging Market To Lead The Way While Regulatory Overhang In Respiratory And EU Pricing Pressure Persist
Bristol-Myers Squibb: Pressures To Dominate In The Near Term, Pipeline Will Take Longer To Deliver
AstraZeneca: 2013 Will Be A Transition Year And AZN May Have To Take Some Bold Initiatives
Eli Lilly: Late Stage Pipeline Fickle And Risky
Merck: News-flow from Mega-trial on MRKs cardiology Franchise would reshape Mercks Growth Prospects
Novartis: Back on a Growth Trajectory
Novo Nordisk: Hemophilia Franchise and Thrice Weekly Degludec The Future Drivers
Pfizer: M&A Only Can Drive Further Upside In The Near Term
Sanofi: Solid Base Business, But Upside From Pipeline Will Take Longer To Come About
Global Pharma Sector Industry Tables
Drugs approved by FDA in 2012 with Indications
2. Ongoing Cardiovascular Outcome studies in Diabetes therapy area
3. Ongoing clinical trials in adjuvant breast cancer
4. Consolidated Patent expiry pressure (% loss of revenue) on large cap Innovator
through 2017
5. List of Drug products patent to be expired through 2017
6. Emerging market sales growth by Global Pharma
7. Expected drug approvals in 2013
8. Global Pharma: Dividend yield (2012-2017) and Net cash position in 2017
9. Competitive landscape in acromegaly wrt SOM 230
10. PASSPORT-efficacy and safety comparison: Signifor vs.Sandostatin LAR
11. Select late- & Mid-Stage pipeline: Plaque Psoriasis
12. PHIII clinical data on plaque psoriasis of marketed products
13. Novartis-Patent expiry impact through 2017 and growth drivers
14. Roche- major pipeline molecules with expected filing
15. Roche- Efficacy and safety comparison of TDM1 vs. Trastuzumab+docetaxel in
first-line BC
16. Roche- Ongoing important clinical studies of T-DM1 in late stage her 2 positive
breast cancer
17. Ongoing clinical trials on Biosimilar Rituxan
18. Efficacy target profile of GA101 in clinical studies
19. Clinical data of BRAF inhibitor in metastatic melanoma
20. AZN-PhIIb combo data of lesinurad in gout pts -allopurinol-inadequate
responders
21. AZN-Generic exposure through 2017
22. Pipeline of anti-PD1 mAB
23. SGLT2 inhibitors- clinical data comparison
24. BMY-Key growth drivers
25. BMY-Commercial Potential of future blockbuster
26. BMY-Generic exposures thru 2017
27. Ongoing pivotal clinical studies: Ipilimumab
28. LLY-Patent expiry pressure thru 2017
29. LLY-On going clinical studies Edivoxetine
30. Ongoing PhIII clinical studies of Ramucirumab
31. LLY-Key growth drivers and pressures
32. On-going LABA/LAMA late stage clinical trials
33. DURATION 6 vs. HARMONY 6, 7 clinical data comparison
34. Select oral RA drugs in development
35. Sanofi- 2012 Sales from recently patent expired products
36. Dengue vaccine pipeline development

List Of Tables

Januvia-Market share of DPP-IV inhibitors across major Geographies- first
mover advantage is the key
2. Januvia dominates on efficacy
3. NRx market share of DPP-IV in the US (as on Nov 12)
4. TRx market share of DPP-IV in the US (as on Nov 12)

List Of Figures

Drugs approved by FDA in 2012 with Indications
2. Ongoing Cardiovascular Outcome studies in Diabetes therapy area
3. Ongoing clinical trials in adjuvant breast cancer
4. Consolidated Patent expiry pressure (% loss of revenue) on large cap Innovator
through 2017
5. List of Drug products patent to be expired through 2017
6. Emerging market sales growth by Global Pharma
7. Expected drug approvals in 2013
8. Global Pharma: Dividend yield (2012-2017) and Net cash position in 2017
9. Competitive landscape in acromegaly wrt SOM 230
10. PASSPORT-efficacy and safety comparison: Signifor vs.Sandostatin LAR
11. Select late- & Mid-Stage pipeline: Plaque Psoriasis
12. PHIII clinical data on plaque psoriasis of marketed products
13. Novartis-Patent expiry impact through 2017 and growth drivers
14. Roche- major pipeline molecules with expected filing
15. Roche- Efficacy and safety comparison of TDM1 vs. Trastuzumab+docetaxel in
first-line BC
16. Roche- Ongoing important clinical studies of T-DM1 in late stage her 2 positive
breast cancer
17. Ongoing clinical trials on Biosimilar Rituxan
18. Efficacy target profile of GA101 in clinical studies
19. Clinical data of BRAF inhibitor in metastatic melanoma
20. AZN-PhIIb combo data of lesinurad in gout pts -allopurinol-inadequate
responders
21. AZN-Generic exposure through 2017
22. Pipeline of anti-PD1 mAB
23. SGLT2 inhibitors- clinical data comparison
24. BMY-Key growth drivers
25. BMY-Commercial Potential of future blockbuster
26. BMY-Generic exposures thru 2017
27. Ongoing pivotal clinical studies: Ipilimumab
28. LLY-Patent expiry pressure thru 2017
29. LLY-On going clinical studies Edivoxetine
30. Ongoing PhIII clinical studies of Ramucirumab
31. LLY-Key growth drivers and pressures
32. On-going LABA/LAMA late stage clinical trials
33. DURATION 6 vs. HARMONY 6, 7 clinical data comparison
34. Select oral RA drugs in development
35. Sanofi- 2012 Sales from recently patent expired products
36. Dengue vaccine pipeline development

Global Pressure Homogenizers Market Research Report 2016

2016 Global Pressure Homogenizers Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Pressure Homogenizers industry, focusing on the main regions

USD 2850View Report

Global Mechanical Homogenizers Market Research Report 2016

2016 Global Mechanical Homogenizers Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Mechanical Homogenizers industry, focusing on the main regions

USD 2850View Report

Global Smart Labels Market Research Report 2016

2016 Global Smart Labels Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Smart Labels industry, focusing on the main regions

USD 2850View Report

Global Pharmaceutical Fermenter Sales Market Report 2016

Notes:Sales, means the sales volume of Pharmaceutical FermenterRevenue, means the sales value of Pharmaceutical FermenterThis report studies sales (consumption) of Pharmaceutical Fermenter in Global market, especially in United States, China,

USD 4000View Report

Memphis Pharmaceutical & Chemicals Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Memphis Pharmaceutical & Chemicals Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

Global Pharmaceuticals-Gel Sales Market Report 2016

Notes:Sales, means the sales volume of Pharmaceuticals-GelRevenue, means the sales value of Pharmaceuticals-GelThis report studies sales (consumption) of Pharmaceuticals-Gel in Global market, especially in United States, China, Europe, Japan, focuses

USD 4000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2500
  • Site Licence    $ 5000
  • Enterprisewide Licence    $ 7500
$ 2500

Reports Details

Published Date : Jan 2013
No. of Pages :131
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment